Abstract 4232
Background
Pediatrics and AYA patients with cancer care often reported to receive high intensity medical care at the end-of-life. Especially, one study showed that Taiwanese children are more likely to receive high intensity care within one month from death than Canadian children. In this study, we investigate the current condition of end-of-life care for pediatrics, AYA patients who died at the hospital in Japan.
Methods
Using a multicenter administrative claims database, we identified patients with cancer aged 17 years or younger who died in hospital between July 2012 and March 2017 from 303 acute care hospitals in Japan. Patients’ data included age, gender, diagnosis, length of stay (LOS), use of opioids, the factors related to high-intensity end-of-life care (H-EOL), which comprised factors as follows; iv chemotherapy within 14 days from death, intensive care unit admission, more than one emergency department (ED) visit, more than 14 days hospital admission, and respiratory ventilation within one month from death.
Results
A total of 106 patients who died in 47 hospitals were included. The median age was 9 (0-17) years old and 57 patients (54%) were boys. Patients had brain tumor (n = 37), solid tumor (n = 30), hematologic malignancy (n = 25), other (n = 14). The average LOS was 60 (0-428 days). Fifty-five patients received opioids within 2weeks before their death. Ten patients received home medical care treatment before their death in the hospitals. Iv chemotherapy within 14 days from death was 25 patients (23.6%), intensive care unit admission within one month from death was 17 patients (16.0%), more than one ED visit within one month from death was 70 patients (66.0%), more than 14 days hospital admission was 69 patients (65.0%), and respiratory ventilation within one month from death was 20 patients (18.9%). Forty patients received one, 49 patients received two, 10 patients received three, 5 patients received four H-EOL care factors, respectively. Totally, 98% of patients had at least one H-EOL care factor.
Conclusions
Our study clarified the current situation of end-of-life care in the field of pediatrics, AYA with cancer. The proportion of H-EOL care in Japan is similar to that in Taiwan, and higher compared with that in Canada.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2041 - Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC
Presenter: Jose Trigo Perez
Session: Poster Display session 1
Resources:
Abstract
5444 - Analysis of the tumor microenvironment and tumor genotype through different stages of lung adenocarcinoma
Presenter: Peter Zink
Session: Poster Display session 1
Resources:
Abstract
3124 - Does Progress achieved in the Treatment of Patients with Metastatic Non-Small-Cell Lung Cancer (NSCLC) reach the Elderly Population?
Presenter: Jorune Suipyte
Session: Poster Display session 1
Resources:
Abstract
5142 - Prognostic factors for non-small cell lung cancer patients with driver mutation negative and brain metastases (HOT 1701)
Presenter: Yoshihito Ohhara
Session: Poster Display session 1
Resources:
Abstract
1580 - A novel risk classification system based on nomogram scores to predict survival of patients presenting with brain metastases at the first diagnosis of NSCLC
Presenter: Pengfei Cui
Session: Poster Display session 1
Resources:
Abstract
4442 - Comparison of real-world response rate (rwRR) to RECIST-based response rate in patients with advanced non-small cell lung cancer (aNSCLC)
Presenter: Xinran Ma
Session: Poster Display session 1
Resources:
Abstract
5405 - Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Presenter: Parneet Kaur Cheema
Session: Poster Display session 1
Resources:
Abstract
1893 - SMARCA4 Deficient Non-Small Cell Lung Cancer (NSCLC): A Comprehensive Genomic Profiling (CGP) Study
Presenter: Stephen Graziano
Session: Poster Display session 1
Resources:
Abstract
5582 - Exploring Resistance to Nivolumab [NIV] applying an Immune Genomic Signature (IGS) in advanced pretreated NSCLC [PRINCiPe study]
Presenter: Sara Pilotto
Session: Poster Display session 1
Resources:
Abstract
1408 - DNA damage repair deficiency is associated with early resistance to crizotinib: whole-genome analysis in non-small cell lung cancer patients with ALK-fusion
Presenter: Dongyun He
Session: Poster Display session 1
Resources:
Abstract